Literature DB >> 16141785

G-CSF suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice.

Claire L Gibson1, Nigel C Jones, Malcolm J W Prior, Philip M W Bath, Sean P Murphy.   

Abstract

Granulocyte-colony stimulating factor (G-CSF) is reported to be neuroprotective after transient cerebral ischemia with respect to decreasing lesion volume and enhancing functional recovery. We investigated whether G-CSF is neuroprotective after permanent ischemia and the possible mechanisms underlying this neuroprotection. Mice underwent permanent or 60-minute middle cerebral artery occlusion (MCAO) and received G-CSF (50 microg/kg) or vehicle at the onset or 1 hour post-MCAO. Forty-eight hours after transient MCAO, structural magnetic resonance imaging revealed a significant reduction (50%) in the amount of edematous tissue present in G-CSF-treated mice (p < 0.05). G-CSF treatment also prevented a significant increase in ipsilateral brain water content that was present in vehicle-treated mice after transient (p < 0.05) and permanent (p < 0.001) MCAO. Forty-eight hours after permanent MCAO, G-CSF decreased (50%) the cortical lesion volume (p < 0.05). Using real-time polymerase chain reaction, we found that G-CSF treatment significantly suppressed (p < 0.05) the injury-induced upregulation of IL-1beta mRNA while having no effect on TNFalpha and NOS-2 mRNA expression. This suggests that part of the neuroprotection may be attributed to the ability of G-CSF to reduce the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141785     DOI: 10.1097/01.jnen.0000179196.10032.dd

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  34 in total

1.  Role of the pituitary–adrenal axis in granulocyte-colony stimulating factor-induced neuroprotection against hypoxia–ischemia in neonatal rats.

Authors:  Mélissa S Charles; Robert P Ostrowski; Anatol Manaenko; Kamil Duris; John H Zhang; Jiping Tang
Journal:  Neurobiol Dis       Date:  2012-07       Impact factor: 5.996

2.  Granulocyte colony-stimulating factor treatment provides neuroprotection in surgically induced brain injured mice.

Authors:  Nikan H Khatibi; Vikram Jadhav; Mehdi Saidi; Wanqiu Chen; Robert Martin; Gary Stier; Jiping Tang; John H Zhang
Journal:  Acta Neurochir Suppl       Date:  2011

3.  G-CSF attenuates neuroinflammation and stabilizes the blood-brain barrier via the PI3K/Akt/GSK-3β signaling pathway following neonatal hypoxia-ischemia in rats.

Authors:  Li Li; Devin W McBride; Desislava Doycheva; Brandon J Dixon; Paul R Krafft; John H Zhang; Jiping Tang
Journal:  Exp Neurol       Date:  2015-01-10       Impact factor: 5.330

4.  Neuroprotective therapy using granulocyte colony-stimulating factor for acute spinal cord injury: a phase I/IIa clinical trial.

Authors:  Hiroshi Takahashi; Masashi Yamazaki; Akihiko Okawa; Tsuyoshi Sakuma; Kei Kato; Mitsuhiro Hashimoto; Koichi Hayashi; Takeo Furuya; Takayuki Fujiyoshi; Junko Kawabe; Tomonori Yamauchi; Chikato Mannoji; Tomohiro Miyashita; Ryo Kadota; Masayuki Hashimoto; Yasuo Ito; Kazuhisa Takahashi; Masao Koda
Journal:  Eur Spine J       Date:  2012-03-06       Impact factor: 3.134

5.  G-CSF administration is neuroprotective following transient cerebral ischemia even in the absence of a functional NOS-2 gene.

Authors:  Claire L Gibson; Philip M W Bath; Sean P Murphy
Journal:  J Cereb Blood Flow Metab       Date:  2010-02-10       Impact factor: 6.200

Review 6.  Investigational therapies for ischemic stroke: neuroprotection and neurorecovery.

Authors:  Preeti Sahota; Sean I Savitz
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

7.  Granulocyte-colony stimulating factor for stroke treatment: mechanisms of action and efficacy in preclinical studies.

Authors:  Jens Minnerup; Sevgi Sevimli; Wolf-Rüdiger Schäbitz
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

8.  Administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the intracranial hemorrhage in two dogs: a case report.

Authors:  M H Kang; H M Park
Journal:  Iran J Vet Res       Date:  2016       Impact factor: 1.376

Review 9.  Progress in stem cell therapy for major human neurological disorders.

Authors:  P L Martínez-Morales; A Revilla; I Ocaña; C González; P Sainz; D McGuire; I Liste
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

10.  Anti-neutrophil antibody enhances the neuroprotective effects of G-CSF by decreasing number of neutrophils in hypoxic ischemic neonatal rat model.

Authors:  Desislava M Doycheva; Tiffany Hadley; Li Li; Richard L Applegate; John H Zhang; Jiping Tang
Journal:  Neurobiol Dis       Date:  2014-05-27       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.